Telix Pharmaceuticals (ASX:TLX) has revealed its quarterly revenues, reaffirming its full-year 2024 revenue guidance alongside the numbers.
In a statement, the company said revenue totalled AU$201 million that for the quarter, primarily generated from sales of prostate cancer imaging product Illuccix in its precision medicine business unit.
This represents an increase of 55 per cent from Q3 2023 ($133 million) and an increase of 9 per cent compared Q2 2024 ($189 million).
Telix Pharmaceuticals also continued to deliver strong revenue growth from sales of Illuccix in the U.S. as it executed sales and marketing strategy to drive adoption, increase market share and reinforce its position in the urology market as a leading provider of PSMA3 imaging.
As the company contnues to expand its North American manufacturing footprint, Telix announced the acquisition of RLS (USA) Inc for US$230 million upfront.
“Our achievements over the past quarter reinforce Telix’s leadership in the radiopharmaceutical sector,” Christian Behrenbruch, CEO of Telix Pharmaceuticals, said in a statement. “We continue to make excellent progress across multiple late-stage assets in our therapeutic pipeline, while preparing to commercialise three new imaging agents within our precision medicine portfolio.”
The company will underwent a business reorganization through Q3 which aligned its operations across four business units to reflect its focus as a therapeutics-led radiopharmaceutical company. The updated business model now comprises: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (MedTech), and Telix Manufacturing Solutions (TMS).
For the full year 2024, the company expects revenue to fall between AU$745 million to $776 million, representing an increase of roughly 48 to 54 per cent compared to full year 2023.
Shares of Telix Pharmaceuticals last traded at $21.
Join the discussion: See what HotCopper users are saying about Telix Pharmaceuticals and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.